Licenses Acquired (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended
	Dec. 08, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Upfront license fee		$ 1,500,000
Line of Credit Facility, Frequency of Payments	Additional quarterly payments totaling approximately $13 million related to the Company’s ongoing support of the CAR-T clinical trials currently ongoing at HADASIT, are due through September 2026
Royality payment percentage	5.00%
Research and development expense			$ 1,319,020	$ 629,531
License Agreement Terms [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Research and development expense			$ 630,963
Due Through September 2026 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Annual liecence fee expenses	$ 50,000
Revenues	$ 20,000,000